Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051)
The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease. The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal lymph node radi...
Gespeichert in:
| Veröffentlicht in: | Cancer 1999-10, Vol.86 (8), p.1590-1595 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1595 |
|---|---|
| container_issue | 8 |
| container_start_page | 1590 |
| container_title | Cancer |
| container_volume | 86 |
| creator | WASSERMAN, T. H PETRONI, G. R MILLARD, F. E CHUNG, C.-T BARCOS, M JOHNSON, J. L CANELLOS, G. P PETERSON, B. A |
| description | The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease.
The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features. Fifty-nine patients were enrolled in the study. Fifty-three patients met all study eligibility criteria; 48 of them (91%) had mediastinal disease and 29 (55%) had bulky mediastinal disease.
A complete response (CR) occurred in 35 of the patients (66%). Of all patients who had CR, 26% had the CR after the chemotherapy and before the radiation, and 74% after the chemotherapy and radiation. Twenty percent of the patients who had CR experienced disease progression; in these patients, the progression was outside the radiotherapy field in the lung and involved widespread disease.
EVA offers a nonbleomycin-containing alternative for patients in whom preexisting pulmonary disease may be exacerbated by bleomycin and radiation therapy. EVA, as given in this study (in three cycles), was insufficient chemotherapy for patients who had disease in areas outside the radiation fields (occult disease). |
| doi_str_mv | 10.1002/(SICI)1097-0142(19991015)86:8<1590::AID-CNCR29>3.0.CO;2-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69225276</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69225276</sourcerecordid><originalsourceid>FETCH-LOGICAL-c318t-b2979f558c7f7f2d89b85a2ec0c7c6cc14500c4bdf03b4816c52ab5768329d553</originalsourceid><addsrcrecordid>eNpNUtuO0zAQjRCILQu_gPyAUCuRYjtxYheEVALsRqooYkGCJ8uxna13kzjYyUL5Y_4Cp10uTzNjnTkznnOiaI3gEkGIn88vyqJcIMjyGKIUzxFjDEFEFjRb0ZeIMLharcs3cfG--IjZq2QJl8X2BY7TO9Hsb9fdaAYhpDFJky8n0QPvr0KZY5Lcj04QJDjDDM6iXxf626i7wYgGyJ1u7bDTTvR7MNeD7a03Sj8DN6arGuEH04VCdAoo-8O6sTLSdIvDgx-rwQ6Bo9m3_Q50VmnghDJiMLYDtXWgD2mY48F3M-xAY6VozE-twLlVl9emA8p4Lbw-sI1dLW6sE1WjQe_sZWfDbAlqLYbRaQ9WYA0-7CZ0WYJCdFK7Q99Gj9e6NQKcOTv24DXww6jCVxgkaPEwuleLxutHt_E0-vzu7afiPN5sz8pivYllgugQV5jlrCaEyrzOa6woqygRWEsoc5lJiVICoUwrVcOkSinKJMGiInlGE8wUIclp9PTIGzYPp_UDb42XumlEp-3oecYwJjjPAvDrESid9d7pmvfOtMLtOYJ88gHnkw_4pCifFOV_fMBpximffMB58AE_-oAnHPJiyzFPA_fj2yXGqtXqP-aj8AHw5BYgfJCiduGKxv_DsQxTTJPf4u3FmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69225276</pqid></control><display><type>article</type><title>Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051)</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>WASSERMAN, T. H ; PETRONI, G. R ; MILLARD, F. E ; CHUNG, C.-T ; BARCOS, M ; JOHNSON, J. L ; CANELLOS, G. P ; PETERSON, B. A</creator><creatorcontrib>WASSERMAN, T. H ; PETRONI, G. R ; MILLARD, F. E ; CHUNG, C.-T ; BARCOS, M ; JOHNSON, J. L ; CANELLOS, G. P ; PETERSON, B. A</creatorcontrib><description>The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease.
The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features. Fifty-nine patients were enrolled in the study. Fifty-three patients met all study eligibility criteria; 48 of them (91%) had mediastinal disease and 29 (55%) had bulky mediastinal disease.
A complete response (CR) occurred in 35 of the patients (66%). Of all patients who had CR, 26% had the CR after the chemotherapy and before the radiation, and 74% after the chemotherapy and radiation. Twenty percent of the patients who had CR experienced disease progression; in these patients, the progression was outside the radiotherapy field in the lung and involved widespread disease.
EVA offers a nonbleomycin-containing alternative for patients in whom preexisting pulmonary disease may be exacerbated by bleomycin and radiation therapy. EVA, as given in this study (in three cycles), was insufficient chemotherapy for patients who had disease in areas outside the radiation fields (occult disease).</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19991015)86:8<1590::AID-CNCR29>3.0.CO;2-4</identifier><identifier>PMID: 10526290</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York, NY: Wiley-Liss</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Combined Modality Therapy - adverse effects ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Doxorubicin - therapeutic use ; Etoposide - therapeutic use ; Female ; Follow-Up Studies ; Hodgkin Disease - mortality ; Hodgkin Disease - pathology ; Hodgkin Disease - therapy ; Humans ; Leukopenia - etiology ; Lymph Nodes - pathology ; Lymph Nodes - radiation effects ; Male ; Mediastinal Neoplasms - pathology ; Mediastinal Neoplasms - therapy ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prognosis ; Radiotherapy Dosage ; Remission Induction ; Survival Analysis ; Survival Rate ; Time Factors ; Treatment Outcome ; Vinblastine - therapeutic use</subject><ispartof>Cancer, 1999-10, Vol.86 (8), p.1590-1595</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright 1999 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c318t-b2979f558c7f7f2d89b85a2ec0c7c6cc14500c4bdf03b4816c52ab5768329d553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1962828$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10526290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WASSERMAN, T. H</creatorcontrib><creatorcontrib>PETRONI, G. R</creatorcontrib><creatorcontrib>MILLARD, F. E</creatorcontrib><creatorcontrib>CHUNG, C.-T</creatorcontrib><creatorcontrib>BARCOS, M</creatorcontrib><creatorcontrib>JOHNSON, J. L</creatorcontrib><creatorcontrib>CANELLOS, G. P</creatorcontrib><creatorcontrib>PETERSON, B. A</creatorcontrib><title>Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051)</title><title>Cancer</title><addtitle>Cancer</addtitle><description>The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease.
The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features. Fifty-nine patients were enrolled in the study. Fifty-three patients met all study eligibility criteria; 48 of them (91%) had mediastinal disease and 29 (55%) had bulky mediastinal disease.
A complete response (CR) occurred in 35 of the patients (66%). Of all patients who had CR, 26% had the CR after the chemotherapy and before the radiation, and 74% after the chemotherapy and radiation. Twenty percent of the patients who had CR experienced disease progression; in these patients, the progression was outside the radiotherapy field in the lung and involved widespread disease.
EVA offers a nonbleomycin-containing alternative for patients in whom preexisting pulmonary disease may be exacerbated by bleomycin and radiation therapy. EVA, as given in this study (in three cycles), was insufficient chemotherapy for patients who had disease in areas outside the radiation fields (occult disease).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy - adverse effects</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Doxorubicin - therapeutic use</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hodgkin Disease - mortality</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Leukopenia - etiology</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - radiation effects</subject><subject>Male</subject><subject>Mediastinal Neoplasms - pathology</subject><subject>Mediastinal Neoplasms - therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Radiotherapy Dosage</subject><subject>Remission Induction</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vinblastine - therapeutic use</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNUtuO0zAQjRCILQu_gPyAUCuRYjtxYheEVALsRqooYkGCJ8uxna13kzjYyUL5Y_4Cp10uTzNjnTkznnOiaI3gEkGIn88vyqJcIMjyGKIUzxFjDEFEFjRb0ZeIMLharcs3cfG--IjZq2QJl8X2BY7TO9Hsb9fdaAYhpDFJky8n0QPvr0KZY5Lcj04QJDjDDM6iXxf626i7wYgGyJ1u7bDTTvR7MNeD7a03Sj8DN6arGuEH04VCdAoo-8O6sTLSdIvDgx-rwQ6Bo9m3_Q50VmnghDJiMLYDtXWgD2mY48F3M-xAY6VozE-twLlVl9emA8p4Lbw-sI1dLW6sE1WjQe_sZWfDbAlqLYbRaQ9WYA0-7CZ0WYJCdFK7Q99Gj9e6NQKcOTv24DXww6jCVxgkaPEwuleLxutHt_E0-vzu7afiPN5sz8pivYllgugQV5jlrCaEyrzOa6woqygRWEsoc5lJiVICoUwrVcOkSinKJMGiInlGE8wUIclp9PTIGzYPp_UDb42XumlEp-3oecYwJjjPAvDrESid9d7pmvfOtMLtOYJ88gHnkw_4pCifFOV_fMBpximffMB58AE_-oAnHPJiyzFPA_fj2yXGqtXqP-aj8AHw5BYgfJCiduGKxv_DsQxTTJPf4u3FmA</recordid><startdate>19991015</startdate><enddate>19991015</enddate><creator>WASSERMAN, T. H</creator><creator>PETRONI, G. R</creator><creator>MILLARD, F. E</creator><creator>CHUNG, C.-T</creator><creator>BARCOS, M</creator><creator>JOHNSON, J. L</creator><creator>CANELLOS, G. P</creator><creator>PETERSON, B. A</creator><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991015</creationdate><title>Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051)</title><author>WASSERMAN, T. H ; PETRONI, G. R ; MILLARD, F. E ; CHUNG, C.-T ; BARCOS, M ; JOHNSON, J. L ; CANELLOS, G. P ; PETERSON, B. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c318t-b2979f558c7f7f2d89b85a2ec0c7c6cc14500c4bdf03b4816c52ab5768329d553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy - adverse effects</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Doxorubicin - therapeutic use</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hodgkin Disease - mortality</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Leukopenia - etiology</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - radiation effects</topic><topic>Male</topic><topic>Mediastinal Neoplasms - pathology</topic><topic>Mediastinal Neoplasms - therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Radiotherapy Dosage</topic><topic>Remission Induction</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vinblastine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WASSERMAN, T. H</creatorcontrib><creatorcontrib>PETRONI, G. R</creatorcontrib><creatorcontrib>MILLARD, F. E</creatorcontrib><creatorcontrib>CHUNG, C.-T</creatorcontrib><creatorcontrib>BARCOS, M</creatorcontrib><creatorcontrib>JOHNSON, J. L</creatorcontrib><creatorcontrib>CANELLOS, G. P</creatorcontrib><creatorcontrib>PETERSON, B. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WASSERMAN, T. H</au><au>PETRONI, G. R</au><au>MILLARD, F. E</au><au>CHUNG, C.-T</au><au>BARCOS, M</au><au>JOHNSON, J. L</au><au>CANELLOS, G. P</au><au>PETERSON, B. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051)</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1999-10-15</date><risdate>1999</risdate><volume>86</volume><issue>8</issue><spage>1590</spage><epage>1595</epage><pages>1590-1595</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>The aim of this study was to evaluate a regimen of sequential chemotherapy and radiotherapy for patients with Hodgkin disease.
The Cancer and Leukemia Group B conducted a Phase II study of three cycles of etoposide, vinblastine, and doxorubicin (EVA) chemotherapy followed by subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features. Fifty-nine patients were enrolled in the study. Fifty-three patients met all study eligibility criteria; 48 of them (91%) had mediastinal disease and 29 (55%) had bulky mediastinal disease.
A complete response (CR) occurred in 35 of the patients (66%). Of all patients who had CR, 26% had the CR after the chemotherapy and before the radiation, and 74% after the chemotherapy and radiation. Twenty percent of the patients who had CR experienced disease progression; in these patients, the progression was outside the radiotherapy field in the lung and involved widespread disease.
EVA offers a nonbleomycin-containing alternative for patients in whom preexisting pulmonary disease may be exacerbated by bleomycin and radiation therapy. EVA, as given in this study (in three cycles), was insufficient chemotherapy for patients who had disease in areas outside the radiation fields (occult disease).</abstract><cop>New York, NY</cop><pub>Wiley-Liss</pub><pmid>10526290</pmid><doi>10.1002/(SICI)1097-0142(19991015)86:8<1590::AID-CNCR29>3.0.CO;2-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1999-10, Vol.86 (8), p.1590-1595 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69225276 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Combined Modality Therapy - adverse effects Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Doxorubicin - therapeutic use Etoposide - therapeutic use Female Follow-Up Studies Hodgkin Disease - mortality Hodgkin Disease - pathology Hodgkin Disease - therapy Humans Leukopenia - etiology Lymph Nodes - pathology Lymph Nodes - radiation effects Male Mediastinal Neoplasms - pathology Mediastinal Neoplasms - therapy Medical sciences Middle Aged Pharmacology. Drug treatments Prognosis Radiotherapy Dosage Remission Induction Survival Analysis Survival Rate Time Factors Treatment Outcome Vinblastine - therapeutic use |
| title | Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features : A Phase II Cancer and Leukemia Group B study (9051) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T12%3A23%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20chemotherapy%20(etoposide,%20vinblastine,%20and%20doxorubicin)%20and%20subtotal%20lymph%20node%20radiation%20for%20patients%20with%20localized%20Hodgkin%20disease%20and%20unfavorable%20prognostic%20features%20:%20A%20Phase%20II%20Cancer%20and%20Leukemia%20Group%20B%20study%20(9051)&rft.jtitle=Cancer&rft.au=WASSERMAN,%20T.%20H&rft.date=1999-10-15&rft.volume=86&rft.issue=8&rft.spage=1590&rft.epage=1595&rft.pages=1590-1595&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19991015)86:8%3C1590::AID-CNCR29%3E3.0.CO;2-4&rft_dat=%3Cproquest_cross%3E69225276%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69225276&rft_id=info:pmid/10526290&rfr_iscdi=true |